<?xml version="1.0" encoding="UTF-8"?>
<p id="Par99">The high cost of antiviral therapy and lack of a clear efficacy in these patients highlights the need for effective vaccines against these respiratory viruses. According to the 2013 Infectious Diseases Society of America Guidelines, an intramuscular influenza vaccine is recommended for all immunocompromised patients and HSCT recipients aged 6Â months or older [
 <xref ref-type="bibr" rid="CR30">30</xref>]. It is also desirable to extend the annual immunization to family members and healthcare personnel in contact with the patient [
 <xref ref-type="bibr" rid="CR43">43</xref>]. Even in patients with multiple myeloma, an effective preventive strategy to reduce the risk of influenza is represented by the seasonal influenza immunization. Although patients with multiple myeloma are known to not have high levels of specific anti-influenza antibodies compared to healthy subjects, the vaccine reduces the risk of URTI and the number of hospitalizations. Strategies such as immunization before transplantation or a double-dose schedule improve the immune response [
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
